Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up

Circulation.

Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK

doi: 10.1161/

Cardiovascular Risk and DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

Circulation.

Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group

doi: 10.1161/CIRCULATIONAHA.

Cardiovascular Risk and Diseases

The rise and fall of aspirin in the primary prevention of cardiovascular disease

Lancet.

Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF, Blumenthal RS, McEvoy JW

doi: 10.1016/S0140-6736(19)30541-0.

Lipid-Lowering Drugs

Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention: A Systematic Review of Randomized Clinical Trials

JAMA Cardiol.

Sparrow RT, Khan AM, Ferreira-Legere LE, Ko DT, Jackevicius CA, Goodman SG, Anderson TJ, Stacey D, Tiszovszky I, Farkouh ME, Tu JV, Udell JA

doi: 10.1001/jamacardio.2019.3066.

Cardiovascular Risk and DiseasesMyocardial Infarction

Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial

Lancet.

Näslund U, Ng N, Lundgren A, Fhärm E, Grönlund C, Johansson H, Lindahl B, Lindahl B, Lindvall K, Nilsson SK, Nordin M, Nordin S, Nyman E, Rocklöv J, Vanoli D, Weinehall L, Wennberg P, Wester P, Norberg M; VIPVIZA trial group

doi: 10.1016/S0140-

COMMENTED

Lipid-Lowering Drugs

Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants

Am Heart J.

Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA

doi: 10.1016/j.ahj.2018.12.007.

RECOMMENDED

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Cochrane Database Syst Rev

Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP

doi: 10.1002/14651858.CD011748.pub3

Cardiovascular Risk and DiseasesHypertensionLipid-Lowering DrugsTherapy and Intervention

Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials

Heart.

Selak V, Webster R, Stepien S, Bullen C, Patel A, Thom S, Arroll B, Bots ML, Brown A, Crengle S, Dorairaj P, Elley CR, Grobbee DE, Harwood M, Hillis GS, Laba TL, Neal B, Peiris D, Rafter N, Reid C, Stanton A, Tonkin A, Usherwood T, Wadham A, Rodgers A

doi: 10.1136/heartjnl-

Cardiovascular Risk and DiseasesMyocardial InfarctionThrombosis and Stroke

Effect of Baseline Nutritional Status on Long-term Multivitamin Use and Cardiovascular Disease Risk: A Secondary Analysis of the Physicians' Health Study II Randomized Clinical Trial